Regeneron Increases Stake In ISA Pharma, Plans Pivotal Study

The Netherlands biotech ISA Pharmaceuticals BV is planning a third late-stage clinical study of its candidate immunotherapeutic, ISA101b, in a strengthened collaboration with existing partner Regeneron Pharmaceuticals Inc., in which the US company is also increasing its equity stake in the private European company.

The moves back ISA Pharmaceuticals’ immunotherapeutic approach to the treatment of cancer, in which initial clinical studies has shown ISA101b to be effective when combined with an immuno-oncology compound, or used after chemotherapy has